{"name":"2seventy bio","slug":"2seventy","ticker":"TSVT","exchange":"NASDAQ","domain":"2seventybio.com","description":"2seventy bio is a cell therapy company focused on developing innovative treatments for various types of cancer. The company's pipeline includes several promising candidates, including its lead product, Tavo. With a strong market position in the cell therapy and oncology sectors, 2seventy bio is well-positioned to capitalize on the growing demand for targeted cancer therapies.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Chip Baird (Interim)","sector":"Cell Therapy / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$200M","metrics":{"revenue":85000000,"revenueGrowth":-62.3,"grossMargin":0,"rdSpend":76917000,"netIncome":-57247000,"cash":479510000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Tavo patent cliff ($0.0B at risk)","drug":"Tavo","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"bb21217","genericName":"bb21217","slug":"bb21217","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"bb21217","genericName":"bb21217","slug":"bb21217","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"2seventy bio reported its fourth quarter and full year 2023 financial results, with a net loss of $63.5 million and $244.1 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"2seventy bio Announces Collaboration with Merck to Develop Novel Cancer Therapies","summary":"2seventy bio announced a collaboration with Merck to develop novel cancer therapies using its Tavo platform.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOclJxMGh1dVFISEpLY25URDhNQ0ZISG5nNjZiVDFfRVdrN1BxR2V0VVVXWDJwZzAxa0loX1JCQThJR1Y5X09NZVI1X2hOdnhlQ3drMm5EbHdtYzNfa01GN19tY3hqaHQ3WVloa0xady1YcTl4X2QzYThWUmdyR1dkbjVpaXhadkU4OUM0YVloR3dWYmFYNkNqRXI1Uy1GWE41ZG85b1R0RWNpZWRGMHY0?oc=5","date":"2025-05-13","type":"deal","source":"Investing.com","summary":"2seventy bio completes merger with Bristol-Myers Squibb - Investing.com","headline":"2seventy bio completes merger with Bristol-Myers Squibb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNc1VMVjVmQlNTbUdndnF3XzlkS3FaVGJlclFVYkw5WDN1bnBsMnhEcEt3d1ozN2QxbDNSQTBtV0FxNWpnODhoVkxfS2E4S2tsOHZqWGlGM3VXcUVsSG94NzBGc1EwMmdxcVVKX0RpWlMwWnZPeEx0UmJCQmdjNVYyWXVzUFU4MUlqaC1DbkRRTlBicXJlUmI2d0kzQ1pTbnJyV0tOaVNweVEzZTlFQ3p0REZNSVpmTXB6M0NGTkxHMmhLdGl4RnZ1WF9FS0NCdXhRbktkQ3lhOGRsUklGTVpR?oc=5","date":"2025-03-11","type":"deal","source":"Reuters","summary":"Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters","headline":"Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNHBsMFgtTG5vUnNKUmNLeUwyT3BJckhIUWM4cDNMQm9yWUtMM2VSYmF4NjdaejRRSTY0X0RtVlQ1VlhVN2NtcW5KRld0a0UzellHdzNiSW5HRzVoUmJmTUViSEQzc3RPZVpNSDJlY21oVGFmaFFHaEtfUDkzUHN2aFBPbFRycVZ6UnROWTVmSUM1RFJGaXhNWXdVMy1CZFg5UVl2bURvY0lmekU?oc=5","date":"2025-03-11","type":"deal","source":"MedCity News","summary":"Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal - MedCity News","headline":"Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNLW1YeEpZX0ZsUmw1b2pVS2t4QVBraXJQTi1FZm9ZSS1JX0FUTVl0amJRa0llaEYxSnpiVXc0SlVCTEIyWk85MEpoSm1GazF0UndfNmE4VkR0bTJpb1J1b1FLUmdzMnBrSm00WnpKSWlaM3JqbVhBcF9JVnlIZTV6SmQzUXJiTnc2T1dVci1LQ3hhRkJDLWNsbFYyQVYtM3paVnBGYUFfMHU3LVR6MDh5TmlxSzBQNlk?oc=5","date":"2025-03-11","type":"deal","source":"Fierce Pharma","summary":"In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - Fierce Pharma","headline":"In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxPZnk0S1J0QVJIejQyRGYzRE9aVXFYYzMxbXpxQ3lzSFZ2ckFoSjMyZkxzR1ZZaXNoM1RaMFJ2RWVIeHMtVWhGdEJFZW55VEd3R01oSS1pQTFRbVFDaTlQTnJaQmNUM1I3b2dqdG85dVdZMEFQWE1WR3Bpbjg0YUltRUlTOG1vOWs2TzFKc3Ftc0p5cjN6ZW1JTENCSGktcV85Z1V6MkRPZjJBbklDaTZvb0dtTklRVllvT21IMERNdk8xXy1jbmFzWVJZSEZhLU1SOTdPZ0wtbkttMktuZnk4SmU1Zk80NVNsdkRGV2duX0N3WndoU3BkblZhVWxVejF5SXREak43QVg1YkRrWVhfUDYwOWhoTWh1a0FCUnpJSk4zbFVuM3dkcExBR1BHMVJaVDBZWGlXTDE?oc=5","date":"2024-04-05","type":"regulatory","source":"Bristol Myers Squibb","summary":"U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy - Bristol Myers Squibb","headline":"U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multipl","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPZVJIMTd0YmF1MXBtVWpmWUpBTVgtdm0wWWVuWjU3SExDM3lQaHJteEZhVVBmWkdOenpVWkFhTUk2Z3VMeGZtRVlpdUg3RG84RmRTVnI4SFNvb1BBbUJPNjQ5NkhsS2o4RkFyNm1tSlJ1UTQxVk9sSkRrVnp3UmgzSmRQb2MwblZPYjJUcUN1aTlLTDFoZWY4ZW1mWUljQTAzN2hGaWhkaHN3OHVpYlJBWWlkSHlEOG03SFhiNU5zM19QcWZMYjlqNzlsQlVpeElScThQbVpkQUt2NWJia3ZkU1E4VW5idw?oc=5","date":"2024-04-01","type":"pipeline","source":"Business Wire","summary":"2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron - Business Wire","headline":"2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVFdHUTV4OUdQRkhhUWpXT2phNGNRa00wNVRQOXVDMkZxY0ZodndwMDNwenBuU3N3MF9objRNQVExSUVNaXhxUF9oM1JKb2JmZ2RycXhyeEtWOVJ2YmRVLTFqQzZveVZFQVFUSHZhbHFmbElQM2FkYTZnVTNCb3ZlUm1pRzViVW5tQi1hLVlvQ1VUa2E0SGFCc0YyX3R0Sy16UEtPUkRHMExRUQ?oc=5","date":"2024-01-30","type":"pipeline","source":"Business Wire","summary":"2seventy bio Announces New Strategic Path Forward - Business Wire","headline":"2seventy bio Announces New Strategic Path Forward","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOQzFldG5kcHRycUNvbTRfYTVvVXVVMVZqQ3hNZEd0S0t6bkpmZ0ZZZ1E0THZWeTgtLUFHS19PUVdZYjdTVjI3ck1yNlZnR3o3SzB0R0gydGppS2d2Ti11QUJSQTM4WHdBazlfM1NnN1VKaHhUZ3NvWTMwY1lRbjVZTE5GNjduc1JOZHliUENhRXlVbm1EN25PUmEwSXkxd19WZi1QaTJ2amt3c3pkVkNuWGF0N1E4M2xmQUFZeXhKQWwtSXVENWJSczhWcDZsZw?oc=5","date":"2024-01-30","type":"pipeline","source":"Reuters","summary":"2seventy bio to sell experimental cell therapies, names new CEO - Reuters","headline":"2seventy bio to sell experimental cell therapies, names new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPRDBydWdMYW94RWtTazVKOUhydUJIcFg1bmJNaS1vRGhVTm9ISEtESUV2SWdxb0NGWndSQXFaWjJoald5dTAxdTNRbnFWazB0cUItTXgxR0hJUEVvN2VTT0NVUll3SmRqZDBxZkstdnlQTDFGbUpOTUxCbmVJX2QwNVlsTWppM1IyamZNVEoxemV5WlE?oc=5","date":"2023-11-20","type":"regulatory","source":"Barron's","summary":"Bristol Myers Squibb Stock Falls After Delay to Gene Therapy Drug Approval - Barron's","headline":"Bristol Myers Squibb Stock Falls After Delay to Gene Therapy Drug Approval - Barron's","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOeEVsTUR0bU1nTXkyZjlVWG1DdWR5bkhlMGp0Znl1UWdtOXVCMk9RRzZUYmUxZXg2VElvVXhTQjNEaXlmN0ZwN0d3TmE1NWl0TEpUWUdTN1cxWnJXeG9fejMzbTlUeHNxRTlLT216dW9obUR4TTUzTkYwZ3Nzc2dSVGg5NEF6Vk1TSTdadUl3MzNiS1hkd1NhY09DbjB2QQ?oc=5","date":"2023-06-21","type":"pipeline","source":"Seeking Alpha","summary":"2seventy bio: Nothing Properly Explains The Low Valuation (NASDAQ:TSVT) - Seeking Alpha","headline":"2seventy bio: Nothing Properly Explains The Low Valuation (NASDAQ:TSVT)","sentiment":"neutral"}],"patents":[{"drugName":"Tavo","drugSlug":"tavocept","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Oncology","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":37862000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":37862000,"period":"2024-12-31"},{"value":100387000,"period":"2023-12-31"},{"value":100387000,"period":"2023-12-31"},{"value":91496000,"period":"2022-12-31"},{"value":91496000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":76917000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-57247000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":479510000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}